RITONAVIR (r), 25mg, tab.

NST DORARITO2T-

Outdated Article


Article is intended to be used with children (<12 years) ONLY.
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AE03
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.

OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

https://msf.oodin.sh/web/image/product.template/569719/image_1920?unique=1826e0d

This combination does not exist.

Add article to list

   

Add Kit To Wishlist

   

RITONAVIR (r)

Therapeutic Action

Antiretroviral, protease inhibitor (PI)

Indications

Booster for protease inhibitors (darunavir, lopinavir, atazanavir) in HIV infection. Not used as an antiretroviral on its own.

Combination of darunavir / ritonavir is the preferred boosted protease inhibitor option for ART if a protease inhibitor is needed.

Combinations of atazanavir + ritonavir or lopinavir + ritonavir can be used as alternatives if darunavir / ritonavir cannot be used.

Instructions for use

Ritonavir should not be used alone but in combination with other protease inhibitors.

Fixed-dose combinations (FDC) are available:

  • DRV eq. 400mg base / r 50mg, tab.
  • ATV 300mg / r 100mg, tab.
  • LPV 40mg / r 10mg, granules, sachet
  • LPV 100mg / r 25mg, tab.
  • LPV 200mg / r 50mg, tab.

The 100 mg ritonavir tablet may be required to boost darunavir in patients with TB who are on protease inhibitor-based ART.

Storage

Below 25ºC